key: cord-0988777-1dqw3l9a
authors: Khaki-Khatibi, Fatemeh; Qujeq, Durdi; Kashifard, Mehrdad; Moein, Soheila; Maniati, Mahmood; Vaghari-Tabari, Mostafa
title: Calprotectin in Inflammatory Bowel Disease
date: 2020-08-18
journal: Clin Chim Acta
DOI: 10.1016/j.cca.2020.08.025
sha: 1a8bbcd02ee5da2110ed5b3829e5f37117057c67
doc_id: 988777
cord_uid: 1dqw3l9a

Abstract The term IBD is usually used for referring to a group of inflammatory gastro-intestinal diseases (mainly Crohn's disease and ulcerative colitis). Accordingly, IBD arises as a result of inappropriate immune response to intestinal commensal organisms among genetically susceptible individuals. Performing colonoscopy and histopathologic evaluation on an inflamed bowel biopsy specimen are currently considered as gold standards for diagnosis and management of IBD.Correspondingly, these techniques are known to be invasive and costly. In recent decades, fecal calprotectin, as a biomarker, has received much attention for the diagnosis and non-invasive management of IBD.Up to now, many studies have investigated the efficacy of fecal calprotectin in the areas of IBD differentiation from IBS, prediction of endoscopic and histologic activities of IBD and prediction of disease recurrence. Although some of these studies have reported promising results, some others have shown significant limitations. Therefore, in this paper, we reviewed the most interesting ones of these studies after a brief discussion of the laboratory measurement of fecal calprotectin. Moreover, we attempted to provide an answer for the question of whether fecal-calprotectin could be considered as a potential surrogate marker for colonoscopy.

addition to the suffering from inflicts on the patients, it also has many negative effects on society.

Moreover, many financial burdens are annually imposed on countries for controlling and treating this chronic disease. The invasive diagnostic and therapeutic measures are currently undertaken to diagnose and manage IBD, which are unpleasant for patients as well as having the high associated costs. Now, the gold standard method for diagnosing IBD and monitoring patient status is performing colonoscopy examination and histopathologic evaluation, which are invasive measures (13) . Therefore, in recent years, many studies have been conducted to find a suitable laboratory marker with sufficient sensitivity and specificity for the purpose of diagnosing and non-invasive management of IBD. A high proportion of these studies have investigated the efficacy of fecal calprotectin in diagnosing and monitoring patients. Although some of these studies reported auspicious results, there are still some doubts on the effectiveness of fecal calprotectin on diagnosing and monitoring IBD patients. So, in this review, we addressed the advantages and limitations of fecal calprotectin for the diagnosis and management of IBD.

The efficacy of fecal calprotectin, as an laboratory marker, in various areas of IBD diagnosis and management have been studied including IBD differentiation from irritable bowel syndrome (IBS), evaluation of endoscopic activity of the disease, evaluation of histological activity of the disease, and prediction of disease recurrence and response to treatment. In following, after a brief introduction and mentioning the important points regarding laboratory measurement of fecal calprotectin, we reviewed the most interesting findings in all of the above-mentioned areas.

Calprotectin is an antimicrobial protein mainly secreted by neutrophils. This protein competes with bacteria over zinc, thus kills the bacteria. However, this is not the only contribution that it has to antimicrobial activity. Moreover, this protein has many potential clinical applications, such as the elevated serum levels that have been observed under various immunological and immunopathological conditions. Serum calprotectin levels rapidly increase in response to bacterial infections in the kidney and heart or during transplant rejection. At the early stages of inflammation of the lung, serum calprotectin can also be considered as a reliable marker; besides, plasma levels of calprotectin appear to be useful in reflecting disease activity in inflammation of the joints (14) . In addition, it has been demonstrated that serum calprotectin levels are increased in patients with bacterial sepsis, so it can be considered as a reliable biomarker (15) . In Neonatal Sepsis, the serum level of calprotectin increases, as well as a sensitivity of 62.5% and a specificity of 69.7% that have been reported for serum calprotectin in diagnosis of Neonatal Sepsis (16) . It has been recently shown that serum calprotectin levels increase in patients with aneurysmal subarachnoid hemorrhage, and higher levels in the first 48 of onset are associated with a poor prognosis at the first three months (17) . Serum calprotectin levels also increase in patients with rheumatoid arthritis, and even in patients with a moderate to high disease activity who have normal or low CRP levels, so they appear to be more efficient at reflecting disease activity (18) .

Some studies have also investigated the efficacy of serum calprotectin in the diagnosis of cancers.

Correspondingly, in one of these studies, it was shown that serum calprotectin levels significantly increased in patients with laryngeal carcinoma compared with healthy individuals and those with benign laryngeal pathologies. Moreover, in this study, a direct relationship was also observed between serum levels of calprotectin and stage of cancer (19) . Another study showed that the serum level of calprotectin increased in patients with papillary thyroid carcinoma, but it significantly decreased after operation (20). Also, regarding the efficacy of serum and saliva calprotectin for the diagnosis of IBD, impressive results have been reported (21, 22). A study on patients with IBD (both UC and CD) have shown that serum calprotectin levels were directly correlated with fecal calprotectin levels and were more potent in IBD diagnosis compared to CRP and albumin. This study also indicated that the combination of serum calprotectin with CRP or albumin can be helpful in the prediction of treatment escalation, especially in patients with CD (23). However, no significant correlation was observed between serum calprotectin and fecal calprotectin levels in patients with CD and UC, as well as a slight correlation between serum calprotectin level and CRP that was observed only in patients with UC (24).

Another study showed that the serum level of calprotectin was significantly higher in patients with CD compared to healthy individuals. In addition, although a significant correlation was observed with the clinical activity of the disease, no significant correlation was found between the level serum calprotectin and endoscopic activity of the disease (25). The efficacy of salivary calprotectin in the diagnosis of IBD has also been studied, which showed that salivary calprotectin significantly increased in patients with IBD compared to healthy individuals. In this study, AUC values for unstimulated saliva and stimulated saliva to distinguish IBD patients from healthy individuals were reported to be 0.927 and 0.870, respectively (22). However, the popularity of calprotectin is mainly due to the use of fecal calprotectin in the diagnosis and management of IBD that is discussed in the following.

Fecal calprotectin is a stable protein that remains stable for 4-7 days at room temperature (26). This property is an excellent advantage for a laboratory marker. Also, it seems that keeping the specimen at refrigerated temperature (4 C) can increase the stability of fecal calprotectin (27). However, evidence has been obtained regarding that the stability of this protein decreases after staying for three days at room temperature. On the other hand, it is not also recommended to keep samples in the refrigerator for more than 7 days (28). It seems that fecal calprotectin remains stable up to one year at -20C (29).

Measurement of fecal calprotectin can be done both qualitatively and quantitatively. Accordingly, in the qualitative measurement, monoclonal antibodies are used to detect fecal calprotectin, and the positive results are characterized by the appearance of colored lines on the test cassette. However, in the qualitative one, only positive or negative results are reported, and despite 93% of sensitivity, test specificity in the evaluation of disease activity was reported to be only 50%. It seems that the main application of this test is to differentiate healthy individuals from IBD patients rapidly; however, some studies have shown that it is not accurate enough in this case, as well (30-32). Nevertheless, a significant concordance has been reported between home test results (IBDoc) and fecal calprotectin laboratory measurement results (when Quantum Blue calprotectin ELISA kit was used). Notably, the agreements between results were 80% and 92% depending on the selected cut-offs (33). Several commercial kits are also available for fecal calprotectin qualitative test known as rapid calprotectin. These tests report positive results ranged from 3 0 to 300 µg/g. There are also several commercial kits that can be used for the quantitative measurement of fecal calprotectin. These kits are usually designed in terms of the ELISA method, and some have a measurement range between 6.5 and 2100 µg/g. Moreover, the chemiluminescence immunoassays (CLIA) method can also detect values between 5 and 8000 µg/g. Fluoro enzyme immunoassays (FEIA) and particle enhanced turbidimetric immunoassays (PETIA) can also be used for the measurement of fecal calprotectin. In this regard, one of the most serious challenges to the laboratory evaluation of fecal calprotectin is the determination of the upper limit in healthy individuals. Among healthy adults, there is a significant agreement on 50 µg/g as an upper limit. One study suggested values up to 112 µg/g in people over 60 years old and up to 186 µg/g in children aged between 2 and 9 years old, as reference ranges of fecal calprotectin in healthy individuals (34).

Fecal calprotectin levels appear to be higher in healthy infants and children under four years old than in adults, and further studies are needed in this regard to determine the acceptable upper limit for diagnosis of pediatric IBD (35, 36). Table 2 lists the median levels of fecal calprotectin in healthy individuals with different ages reported in some studies. According to these reports, age can affect fecal calprotectin levels. 

Only a small percentage of patients complaining of abdominal pain and diarrhea have IBD. In many cases, IBS, as a functional gastrointestinal disorder, is known as the cause of such clinical symptoms. 75%, specificity: 67%) were reported for fecal calprotectin in this regard (54). Furthermore, in one study that examined the efficacy of fecal calprotectin in predicting wireless capsule endoscopy findings, a sensitivity of 59% and a specificity of 71% were reported for this biomarker at 50 μg/g in the diagnosis of small bowel inflammation in Crohn's disease (55). Given these findings, it seems that fecal calprotectin has no ideal sensitivity and specificity for the diagnosis of IBD, where the small intestine is involved. Besides, there are some pre-analytical limitations, which are explained in the next sections.

Therefore, optimistically speaking, fecal calprotectin measurement can eliminate the need for colonoscopy. However, in a meta-analysis performed to evaluate the efficacy of fecal calprotectin and some other inflammatory markers to differentiate between IBD and IBS, the probability of IBD was less than 1% at fecal calprotectin values lower than 40 µg / g or CRP values lower than 0.5 mg/dL (56) .

Therefore, it seems that fecal calprotectin can be helpful, at least in ruling out the possibility of IBD in patients with IBS-like symptoms as well as reducing the rate of colonoscopy. Moreover, it should be noted that, although a systematic review has reported pooled sensitivity and specificity above 90% for fecal calprotectin to differentiate between IBD and IBS, it emphasized more on the possibility of falsepositive results in low cut-off points (57) . Hence, performing extensive studies in different countries on the healthy population and the IBD patient is be needed to determine a suitable cut-off with maximum sensitivity and specificity and minimum false-positive results. Table 3 summarizes the results of various clinical investigations regarding fecal calprotectin utility in the differential diagnosis of IBD from IBS, and Table4 summarizes some meta-analysis results in this regard. As shown in Table 3 , the most important limitation of the majority of clinical studies conducted to date, is the small sample size. A large global study may be helpful in providing a more precise evaluation of fecal calprotectin clinical value in discrimination between IBD and non-IBD diseases. 

Undoubtedly, one of the most serious challenges in the management of IBD is evaluating the endoscopic and histologic activities of the disease. Nowadays, colonoscopy and histopathologic examinations are the routine tools for the assessment of mucosal healing in patients with IBD. As noted earlier, several scoring systems have been devised to score disease activity based on the findings of colonoscopy and histopathologic examinations. In recent years, many promising results have been reported regarding the correlation between these scores and fecal calprotectin levels. In addition, many studies have been performed in the last decade, all of which cannot be reviewed in this article. The first evidence of a link between fecal calprotectin and disease endoscopic activity was obtained in the late 1990s. In one of the first studies, Roseth et al. found a significant correlation between fecal calprotectin levels and endoscopic and histologic activities in patients with ulcerative colitis (41) . Furthermore, in another study, they observed that IBD patients who were in remission clinically and had normal fecal calprotectin levels (less than 50 mg / L) had normal colonoscopy results (66 (71) . In another study, the sensitivity and specificity of fecal calprotectin at a cutoff of 250 µg / g for differentiating MES ≤ 1 in patients with ulcerative colitis were 67% and 77%, respectively (72) . Overall, as presented in Table 5 , several studies performed in different countries reported the correlation between fecal calprotectin and IBD endoscopic activity. Although some of these studies reported a strong correlation, some others reported a relatively weak correlation. As noted earlier, there are significant differences between the reports on the sensitivity and specificity of fecal calprotectin to predict the endoscopic activity of IBD. Undoubtedly, a wide range of factors, from sample size and the inclusion/exclusion criteria to pre-analysis variables and indexes used to evaluate the endoscopic activity, may also contribute to these differences. However, fecal calprotectin does not appear to be a very reliable marker for the prediction of IBD endoscopic activity, so currently it seems a bit optimistic to consider fecal calprotectin as a reliable alternative for colonoscopy. In this regard, further studies are still needed. However, under some certain circumstances such as pregnancy or pandemics, the use of fecal calprotectin to evaluate IBD endoscopic activity can be helpful.

recommended that colonoscopy should be only performed in the second trimester of pregnancy and where there is a strong indication (73) . Therefore, noninvasive markers such as fecal calprotectin can be helpful during pregnancy. In one study, physician global assessment [PGA], which is a clinical symptom-based criterion, was used to evaluate IBD activity, and subsequently the association between fecal calprotectin and this criterion was investigated in pregnant women with IBD. The results of this study showed a significant correlation between fecal calprotectin and PGA levels at pre-pregnancy, during pregnancy, and postpartum stages (74) . In another study, a significant association was reported between fecal calprotectin levels and clinical activity of IBD in pregnant women. Moreover, it was shown that stool calprotectin at a cutoff of 200 mg / kg had a sensitivity between 69.7% -80.0% as well as a specificity between 66.7% -73.3% in the assessment of IBD clinical activity at different stages of pregnancy (75) . A recently published systematic review has also confirmed the conclusions obtained from these studies (76) . According to these results, it seems that fecal calprotectin is not affected by physiological changes during pregnancy; however, it is significantly correlated with IBD clinical activity during pregnancy. Therefore, from the viewpoint of relatively acceptable sensitivity and specificity in predicting the endoscopic activity of IBD, fecal calprotectin may be considered as a noninvasive biomarker for the evaluation of IBD endoscopic activity in pregnant women. In addition, under pandemic conditions, fecal calprotectin can be very helpful. Following the COVID-19 pandemic, which began in late 2019 and is still ongoing, healthcare systems in different countries were forced to impose significant limitations on colonoscopy. Therefore, non-invasive IBD management and fecal calprotectin, as a non-invasive laboratory marker, have become more important than before. The combination between disease clinical activity and fecal calprotectin has been recommended as a noninvasive approach that can help in making decisions on treatment during COVID-19 pandemic (77) .

Therefore, it seems that, fecal calprotectin can be considered as an alternative for colonoscopy used for IBD endoscopic activity evaluation during pandemic. Fecal calprotectin appears to be associated with IBD histologic activity, as well. Given the difficulty in the evaluation of the histologic activity of Crohn's disease (78) , some studies have been focused on the ulcerative colitis, and many scoring systems have been devised, so far. Correspondingly, these systems score the disease's histologic activity based on histologic observations. Therefore, for this purpose, a biopsy of the intestinal tissue is required, which can be prepared by colonoscopy and then sent to the laboratory. In this regard, one of these histologic scoring systems is Robert's score that was used in one of our recent studies where we observed a significant correlation between the level of fecal calprotectin and the histologic activity of ulcerative colitis, which was calculated based on the Robert's scoring system (79 (81) . In a recent study, the Geboes index has been used to evaluate histologic activity in patients with clinically quiescent ulcerative colitis.

As a result, this study reported relatively low sensitivity and specificity for fecal calprotectin in the prediction of Geboes score <3.1 (54% sensitivity, 69% specificity, and cut off 135 µg/g) (71) . In another recent study, the Nancy Index has been used to evaluate the histologic activity of ulcerative colitis, and a high sensitivity (100%) and a low specificity (48%) were finally reported for fecal calprotectin at a cutoff of 72 µg/g in the prediction of histologic activity (82) . However, some studies have reported both high sensitivity and specificity for fecal calprotectin in the prediction of histological remission. For example, one study reported a sensitivity of 100% as well as a specificity of 77% for fecal calprotectin at a cutoff of 100 µg/g in the prediction of GS<3.1 (83) . It seems that the cause of these conflicts should be explored in the endoscopic and clinical activity of the disease, the inclusion and exclusion criteria of these studies, and possibly in the different indexes used for the evaluation of the histologic activity of the disease. Another notable issue is that all of these studies have been conducted on a relatively low number of patients with ulcerative colitis, so the need for a study with a large sample size is still strongly felt. Moreover, a large global study may be helpful in this regard. 

As mentioned previously, IBD has recurrence and relief periods, so predicting response to treatment and relapse is one of the significant challenges in IBD management. The first evidence of the efficacy of fecal calprotectin to predict recurrence dates back to the early 2000s. Accordingly, a study published in 2000 by Tibble et al. is one of the first studies in this regard. In this study, 80 IBD patients in clinical remission were followed up for one year for the assessment of recurrence after preparing a stool sample to measure calprotectin. This study has also shown that fecal calprotectin levels were higher in IBD patients with recurrent disease and it was found that fecal calprotectin had a sensitivity of 90% and a specificity of 83% at a cut-off of 50 mg / L to predict IBD recurrence (91) . In a study published in 2004, Costa et al. showed that the sensitivity and specificity of fecal calprotectin to predict ulcerative colitis recurrence are more than that of Crohn's disease (a sensitivity of 89% and a specificity of 82% versus a sensitivity of 87% and a specificity 43% at a cutoff of 150 μg/g) (92) . Another study conducted on patients with ulcerative colitis has also reported appropriate sensitivity and specificity rates for fecal calprotectin in the prediction of relapse (a sensitivity of 80% and a specificity 89% at a cutoff of 341 μg/g). However, another study was conducted on 64 patients with ulcerative colitis who have been Followed-up for 1 year, and finally a lower sensitivity was reported. This study have shown that fecal calprotectin at cutoff of 250 μg/g could predict disease relapse with 41% sensitivity and 85% specificity (93). A study on 65 patients with Crohn's disease treated with infliximab and in remission reported a sensitivity of 61% as well as a specificity of 48% for fecal calprotectin at a cutoff of 130 μg/g, to predict the recurrence of Crohn's disease (94) . Meanwhile, another study on 53 patients with Crohn's disease reported higher sensitivity and specificity rates in this regard (a sensitivity of 80% and a specificity 90.7 at a cutoff of 340 μg/g) (95) . In another study on 163 patients with IBD who were followed up for six months, a sensitivity of 69% and a specificity of 69% were reported at a cut-off of 150 μg/g. However,

this study showed that only if patients with colonic CD or recurrence within the first 3 months were considered, the sensitivity of fecal calprotectin to predict recurrence would be 100% (96) . In another study on patients with IBD treated with Infliximab, the sensitivity and specificity of fecal calprotectin to predict recurrence at a cut-off of 160 μg/g were obtained as 91.7% and 82.9%, respectively (97) .

In patients treated with anti-tumor necrosis factor (TNF) drugs, sensitivity and specificity were 100% and 80% at a cut-off of 130 μg/g, respectively (98). However, in a meta-analysis conducted on 6

prospective studies and a total of 672 IBD patients (318 UC patients and 354 CD patients), the sensitivity and specificity of fecal calprotectin to predict IBD recurrence were achieved as 87% and 73%, respectively (99) . In a recent meta-analysis that focused only on ulcerative colitis, 75 % sensitivity and 77% specificity were reported for fecal calprotectin in the prediction of disease recurrence (100).

The results of these meta-analyses showed that, although fecal calprotectin measurement is an easy and non-invasive approach, its value in predicting recurrence is less than expected. In addition, it seems that fecal calprotectin has no preference for CRP in the prediction of postoperative endoscopic recurrence in Crohn's disease, and even CRP, despite having a lower sensitivity (57.1% versus 85.7%), has a higher specificity compared to fecal calprotectin in this regard (85.7% versus 45.9% ) (101) . It seems that fecal calprotectin can also be effective on predicting the progression of the disease and some events such as surgery and hospitalization. In a recent study performed in the UK, 918 patients with CD were followed up (the median follow-up period was 50.6 months) and disease progression was monitored based on hospitalization, surgery ,and Montreal classification system. Finally, a relationship was investigated between fecal calprotectin level and disease progression in 877 of these patients. Accordingly, in this study multivariable Cox proportional hazards analysis showed that long-term increase in disease progression was independently associated with the increased fecal calprotectin levels by passing 3 month or more from the CD diagnosis Agents, can predict the risk of clinically active disease in the next year with a sensitivity of 72% and a specificity of 80% (104) .

Given the results of this study, it seems that failure in reducing fecal calprotectin after anti-TNFα therapy may indicate a poor response to this treatment. In another study conducted on patients with acute etiologic ulcerative colitis, it was shown that fecal calprotectin (at a cutoff of 1000 μg/g) on day 3

of corticosteroid therapy could predict response to treatment with 71% and 75% sensitivity and specificity, respectively (105) . In another study, the sensitivity and specificity of fecal calprotectin for the prediction of response to corticosteroid therapy were 84.6% and 60.7% in acute severe ulcerative colitis at a cut-off of 1005 μg/g, respectively (106) . In acute severe ulcerative colitis, corticosteroid therapy is regarded as the first line of treatment, and if treatment fails, rescue therapy or surgery should be performed instead of that. Since some studies have shown that delaying surgery would have some adverse effects on these patients (107), the existence of a biomarker that can predict response to corticosteroid therapy with appropriate sensitivity and specificity , can be beneficial in saving time as well as in selecting the appropriate therapeutic approach. Therefore, the efficacy of fecal calprotectin should be further studied in this regard. Given all the above mentioned reports, fecal calprotectin seems to have relatively good sensitivity and specificity rates in predicting recurrence and response to treatment, especially in ulcerative colitis. Although fecal calprotectin may not be an ideal marker, given the ease of its measurement, it can be considered as a non-invasive predictor of relapse and response to treatment. The results of some interesting studies regarding the fecal calprotectin utility in prediction of relapse in IBD patients are summarized in Table 6 . 

Several studies have also shown that fecal calprotectin, as a noninvasive biomarker, may have some potentially useful applications in the diagnosis and management of IBD. However, similar to any other laboratory markers, there are some limitations to be considered. As mentioned in the previous sections, although calprotectin is considered to be highly resistant to proteolysis and capable of holding the sample for up to 7 days at room temperature, it has been recently shown that after six days, fecal calprotectin concentration might decrease by about 35% (27, 115) . In one study, stability remained for three days, and a 28% decrease was also reported in mean calprotectin concentration after seven days of storage at room temperature. The sample isolated with extraction buffer seems to have a much lower stability, and a 46% decrease was also reported in the extracted calprotectin concentration after six days at room temperature (27). These are some limitations of the pre-analysis that should be considered seriously. To overcome these limitations, it is recommended to keep the stool sample for up to 10 days at 2-8 ° C or for one year at -20 ° C. The extracted sample also appears to be stable for a 6-month period at -20C (116) . In addition, a significant intra-individual fecal calprotectin variability has been reported in IBD patients, which may lead to misdiagnosis (117) . Another limitation to be considered is the effect of certain drugs and some diseases on the concentration of fecal calprotectin. Among these drugs, NSAIDs usage appears to increase the level of fecal calprotectin, and one study has shown that Indomethacin and naproxen can increase basal fecal calprotectin concentrations to more than twice (118) . Proton pump inhibitors also appear to be able to increase the fecal calprotectin concentration significantly (119) . The high prevalence of the above-mentioned medications can be considered as a serious limitation for fecal calprotectin. Therefore, in people who regularly consume these medications, the results of a fecal calprotectin test may not be very reliable. The elevated fecal calprotectin levels cannot be solely attributed to IBD, and fecal calprotectin levels may also increase in some other diseases. In this regard, the most important diseases are colorectal cancer, infectious diarrhea, celiac disease, diverticular disease, ankylosing spondylitis, pancreatitis, gastroesophageal reflux disease, and food allergies (120) .

Therefore, in interpreting the results of fecal calprotectin test, the presence of the aforementioned diseases should be considered. 

Inflammatory bowel disease

Dysbiosis in inflammatory bowel disease

Evaluation of the Potential Antioxidant Role of High-Density Lipoprotein-Cholesterol (HDL-C) in Patients with Ulcerative Colitis

From Genetics to Epigenetics, Roles of Epigenetics in

Guidelines for the management of inflammatory bowel disease in adults

Guidelines for the management of inflammatory bowel disease in adults

Extraintestinal manifestations of inflammatory bowel disease

Fistulas to the urinary system in Crohn's disease: clinical features and outcomes

Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology

Current global trends in the incidence of pediatric-onset inflammatory bowel disease

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of populationbased studies

What is the peak age for onset of IBD?

Role of endoscopy in inflammatory bowel disease

Calprotectin -a pleiotropic molecule in acute and chronic inflammation

Calprotectin and calgranulin C serum levels in bacterial sepsis

Serum Calprotectin: A Potential Biomarker for Neonatal Sepsis

Early Serum Calprotectin (S100A8/A9) Predicts Delayed

Cerebral Ischemia and Outcomes after Aneurysmal Subarachnoid Hemorrhage

Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI

Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study

Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein

Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy

Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease

Fecal calprotectin, MMP-9, and human betadefensin-2 levels in pediatric inflammatory bowel disease

Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue? JGH Open

Fecal calprotectin Level in patients with IBD and noninflammatory disease of colon: a study in Babol

Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders

A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients

A meta-analysis of the utility of Creactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome

Faecal calprotectin concentrations in gastrointestinal diseases

Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders

Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

Faecal calprotectin in suspected paediatric inflammatory bowel disease

Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: metaanalysis

The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and metaanalysis

Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, Creactive protein, platelets, hemoglobin, and blood leukocytes

Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis

Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis

Guidelines for endoscopy in pregnant and lactating women

Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease

Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease

Bowel Disease Activity in Pregnancy: A Systematic Review

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19

Current best practice for disease activity assessment in IBD

Fecal Calprotectin With Serum Antioxidant Enzymes in Patients With Inflammatory Bowel Disease: Accidental Numerical Correlation or a New Finding?

Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis

Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis

Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease

neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease

Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis

Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease

Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease

Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study

Prediction of

Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study

Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy

Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study

Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies

Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis

Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease

Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease

Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents

Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study

Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis: A prospective observational study

Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications

Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control

Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases

Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy

Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis

Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study

Faecal calprotectin in children with clinically quiescent inflammatory bowel disease

Can calprotectin predict relapse risk in inflammatory bowel disease?

Faecal markers of gastrointestinal inflammation

Chapter Six -Fecal Calprotectin

Fecal calprotectin variability in Crohn's disease

Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs

Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity

Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review

We would like to express our gratitude to department of Clinical Biochemistry and Laboratory Medicine of Tabriz University of Medical Sciences and our friends for their support and willingness to spend their valuable time with us to read manuscript.We thanks Hormozgan University of Medical Sciences. We also thanks Dr. Mark Silverberg for his helpful suggestions.

All authors declare there is no conflict of interest

Not Applicable